<?xml version="1.0" encoding="UTF-8"?>
<p>Adult hematologic malignancy patients lacking an available HLA-matched sibling with an available 8/8 (
 <italic>HLA-A, -B, -C, -DRB1</italic>) matched unrelated donor (MUD) or 1-antigen/allele mismatched related donor (MMRD) or mismatched unrelated donor (MMUD) were enrolled on the trial between January 2013 and November 2015. Patients with HIV infection, active hepatitis B or C disease, abnormal renal (serum creatinine &gt; upper limit of normal [ULN] with clearance &lt;40 mL/min/1.73m2 body surface area [BSA]) or liver function (serum total bilirubin &gt;ULN, serum alanine/aspartate aminotransferase &gt;2x ULN), Eastern Cooperative Oncology Group (ECOG) performance status &gt;2, hyperlipidemia (serum cholesterol &gt;300mg/dL; trigylcerides &gt;400mg/dL) despite therapy, and peripheral neuropathy â‰¥grade 2 within 21 days prior to transplantation were excluded.
</p>
